Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate

• Published in: Veterinary research (Paris) 2021-05, Vol.52 (1), p.1-74, Article 74
• Main Authors: Chen, Nanhua, Li, Shubin, Tian, Yunfei, Li, Xinshuai, Li, Shuai, Li, Jixiang, Qiu, Ming, Sun, Zhe, Xiao, Yanzhao, Yan, Xilin, Lin, Hong, Yu, Xiuling, Tian, Kegong, Shang, Shaobin, Zhu, Jianzhong
• Format: Article
• Language: English
• Subjects: Antibiotics; Antibodies; Antigens; Broadly neutralizing antibodies; Cloning; Cross protection; Design; Genetic diversity; Genetic engineered vaccine; Genetic engineering; Genomes; Glycoproteins; Hogs; Immunization; Infection; Infections; Infectious clone; Laboratories; Life Sciences; Medical research; Medicine, Experimental; ORF2-6 consensus sequence; Proteins; PRRSV; Swine; Vaccination; Vaccines; Viral antibodies; Viral infections; Virulence; Viruses
• ISSN: 1297-9716; 0928-4249; 1297-9716
• DOI: 10.1186/s13567-021-00944-8

Due to the substantial genetic diversity of porcine reproductive and respiratory syndrome virus (PRRSV), commercial PRRS vaccines fail to provide sufficient cross protection. Previous studies have confirmed the existence of PRRSV broadly neutralizing antibodies (bnAbs). However, bnAbs are rarely induced by either natural infection or vaccination. In this study, we designed and synthesized a consensus sequence of PRRSV2 ORF2-6 genes (ORF2-6-CON) encoding all envelope proteins based on 30 representative Chinese PRRSV isolates. The ORF2-6-CON sequence shared > 90% nucleotide identities to all four lineages of PRRSV2 isolates in China. A chimeric virus (rJS-ORF2-6-CON) containing the ORF2-6-CON was generated using the avirulent HP-PRRSV2 JSTZ1712-12 infectious clone as a backbone. The rJS-ORF2-6-CON has similar replication efficiency as the backbone virus in vitro. Furthermore, pig inoculation and challenge studies showed that rJS-ORF2-6-CON is not pathogenic to piglets and confers better cross protection against the virulent NADC30-like isolate than a commercial HP-PRRS modified live virus (MLV) vaccine. Noticeably, the rJS-ORF2-6-CON strain could induce bnAbs while the MLV strain only induced homologous nAbs. In addition, the lineages of VDJ repertoires potentially associated with distinct nAbs were also characterized. Overall, our results demonstrate that rJS-ORF2-6-CON is a promising candidate for the development of a PRRS genetic engineered vaccine conferring cross protection.